GH Research PLC (NASDAQ:GHRS) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of GH Research PLC (NASDAQ:GHRS) have been given an average rating of “Moderate Buy” by the twelve research firms that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $45.00.

Several analysts recently commented on the stock. Wall Street Zen upgraded shares of GH Research from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a research report on Friday, July 17th. Wells Fargo & Company began coverage on shares of GH Research in a report on Monday, July 27th. They issued an “overweight” rating and a $44.00 target price for the company. Cantor Fitzgerald lifted their price target on shares of GH Research from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, Guggenheim boosted their price target on GH Research from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, August 7th.

GH Research Trading Down 6.8%

Shares of GHRS stock opened at $28.19 on Friday. The business’s 50 day moving average is $26.09 and its two-hundred day moving average is $20.55. GH Research has a twelve month low of $11.83 and a twelve month high of $31.44. The company has a market capitalization of $1.93 billion, a P/E ratio of -28.19 and a beta of 1.29.

GH Research (NASDAQ:GHRS) last released its earnings results on Thursday, August 6th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.06. As a group, equities analysts predict that GH Research will post -1.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GH Research

A number of large investors have recently bought and sold shares of GHRS. Barclays PLC boosted its stake in shares of GH Research by 63.4% during the fourth quarter. Barclays PLC now owns 2,118 shares of the company’s stock valued at $27,000 after acquiring an additional 822 shares during the last quarter. North Star Investment Management Corp. acquired a new position in GH Research in the 1st quarter valued at about $31,000. Royal Bank of Canada lifted its holdings in GH Research by 43.1% in the 1st quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock valued at $36,000 after purchasing an additional 780 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in GH Research in the 4th quarter valued at about $38,000. Finally, Osaic Holdings Inc. boosted its stake in shares of GH Research by 63.6% during the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after purchasing an additional 2,400 shares during the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

Key GH Research News

Here are the key news stories impacting GH Research this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for GH Research’s fourth quarter of 2026 and full-year 2026, projecting losses of $0.31 and $1.14 per share, respectively, compared with previous estimates of $0.32 and $1.21. The firm maintained its Buy rating. GH Research analyst estimates
• Positive Sentiment: The analyst also slightly improved quarterly EPS estimates for the second, third and fourth quarters of 2027, reducing projected losses by $0.01 per share in each period. The full-year 2027 loss forecast was raised to $1.62 per share from $1.64.
• Neutral Sentiment: HC Wainwright initiated longer-term EPS estimates of losses totaling $1.76 per share for 2028, $2.11 for 2029 and $1.22 for 2030. These projections suggest continued operating losses for several years, despite expectations for gradual improvement by 2030.
• Negative Sentiment: GH Research is still expected to post a substantial loss, with the current-year consensus estimate near a $1.33-per-share deficit. The absence of near-term profitability may weigh on the stock, particularly after its strong advance toward its 52-week high.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.